ヒストンデセチラーゼ阻害剤のヴォーリノスタットと炭酸アンヒドラゼIIおよびIXの非標的結合
Mitchell C Gulkis1, James T Hodgkinson2, Céleste P Sele3
1Department of Biochemistry and Molecular Biology, University of Florida, 1149 Newell Drive, Gainesville, FL 32610, USA.
まとめ
癌薬であるヴォリノスタット (SAHA) は,炭酸水素 (CA) に結合し,副作用を引き起こす可能性があります. この研究は,SAHA
科学分野:
- 生物化学
- 構造生物学
- 薬剤化学
背景:
- Vorinostat (SAHA) のようなヒストン脱酸化酵素阻害剤 (HDACi) は,がん治療に使用されています.
- SAHAのアイソフォーム選択性の欠如は,亜鉛依存酵素を阻害することによって,標的外効果を引き起こす可能性があります.
- 炭酸水素 (CA) は,意図しない標的となる亜鉛金属酵素である.
研究 の 目的:
- SAHAがヒトの炭酸水素II (CAII) と炭酸水素IX (CAIX) に結合する構造的基礎を調査する.
- SAHAとCAの潜在的非標的相互作用を調査する.
- 新しいCA阻害剤としてのヒドロキサート基化合物の可能性を評価する.
主な方法:
- 室温100Kでの高解像度結晶撮影
- 結合方向を予測するためのSwissDockモデリング.
- ナノDSFを用いた熱転移測定法
- 結合エネルギーの計算
主要な成果:
- SAHAはCA IIとCA IXを模倣し,異なるコンフォマーを採用し,亜鉛イオンに調整する.
- アミノ酸の違いによるCA IIとCA IXミミックの間の水害性相互作用の違いが観察されました.
- スイス・ドックは SAHA 結合状態を正確に予測した.
- SAHAは,アセタゾラミドとは異なり,CAの最小限の安定化を示した.
- 結合エネルギー計算によると,SAHAは,HDACのターゲットに似た親和性を有するCAと結合する可能性がある.
結論:
- SAHAは炭酸水化物と結合し,臨床的副作用を引き起こす可能性があります.
- ハイドロキサマトは,新型の非硫黄胺CA阻害剤の開発の潜在的支柱である.
- CA阻害剤のイソフォーム選択性を達成することは依然として重要な課題です.
関連する概念動画
Drug Binding to Blood Components
249
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
249
Protein-Drug Binding: Mechanism and Kinetics
931
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
931
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
440
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
440
Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446


